Microarray-based genetic analyses for studying susceptibility to arterial and venous thrombotic disorders.

We describe the potential of microarray technology for parallel, high-throughput approaches to molecular detection of DNA variations associated with progression to arterial and venous thrombotic diseases. The use of the newly commercialized NanoChip platform and a framework for genetic screening with a list of potential genetic targets useful to the evaluation of cardiovascular risk are presented. Implementation in clinical setting of analytical silicon and glass microarrays will facilitate early diagnosis, help direct specific advice to high-risk individuals and evaluate treatment strategies.